Is serum C-reactive protein concentration correlated with HbA1c and insulin resistance in Type 2 diabetic men with or without coronary heart disease?
The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
Background and aims C-reactive protein (CRP) is an inflammatory marker that predicts coronary heart disease (CHD) risk. Diabetes mellitus (DM) counts as a CHD risk equivalent. We aimed to compare serum high sensitivity CRP (hs-CRP) levels in Type 2 diabetic (T2DM) men without CHD, non-diabetic CHD patients and T2DM patients with CHD.Subjects and methods Four groups were formed; Group 1 [DM(+), CHD(-), no.=25], Group 2 [DM(-), CHD(+) no.=25], Group 3 [DM(+), CHD(+), no.=25], and Group 4 (controls, no.=30). Serum hs-CRP, insulin, glucose, total, HDL-, LDL- and VLDL-cholesterol, triglyceride levels and homeostasis model assessment for insulin resistance (HOMA-IR) index were determined.Results Mean hs-CRP level of Group 1 (0.6+/-0.29) was not different statistically from Group 2 (1.44+/-0.97). Mean hs-CRP levels were higher in men with CHD, whether they were diabetic (Group 3; 3.83+/-2.01 mg/dl) or non-diabetic (Group 4), than in control subjects (0.16+/-0.15; p=0.0001 and p<0.004, respectively). Mean hs-CRP level of Group 3 was also higher than Group 2 (p=0.0001). There was a positive correlation between serum hs-CRP and glycated hemoglobin (HbA1c; r=0.277, p<0.01), fasting insulin (r=0.336, p<0.02) and HOMA-IR (r=0.348, p<0.02) in T2DM men with or without CHD.Conclusions T2DM men without CHD had similar CRP levels with non-diabetic CHD patients, whereas CRP levels of T2DM men with CHD were higher than non-diabetic men with CHD. Because of a positive correlation between serum hs-CRP and HbA1c, fasting insulin and HOMA-IR, inflammation, insulin resistance and hyperglycemia jointly contribute to the cardiovascular risk in T2DM men.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“High-sensitivity C-reactive protein (hsCRP) is a sensitive biomarker of systemic inflammation reported to be elevated in patients with type 2 diabetes with other underlying comorbidities [3, 4].”
From Impact of semaglutide on high-sensitivity C-reactive protein: exploratory patient-level analyses of SUSTAIN and PIONEER randomized clinical trials (2022) · cites this paper as [4]
Citations
Cites
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,947
Haffner, S. M., Lehto, S., Rönnemaa, T., Pyörälä, K., & Laakso, M. (1998) · New England Journal of Medicine · doi:10.1056/nejm199807233390404 · Cited by 7,000
Ridker, P. M., Hennekens, C. H., Buring, J. E., & Rifai, N. (2000) · New England Journal of Medicine · doi:10.1056/nejm200003233421202 · Cited by 5,850
C-Reactive Protein, Interleukin 6, and Risk of Developing Type 2 Diabetes Mellitus
Pradhan, A. D. (2001) · JAMA · doi:10.1001/jama.286.3.327 · Cited by 4,433
Cardiovascular Survey Methods.
(1968) · Annals of Internal Medicine · doi:10.7326/0003-4819-69-6-1335_2 · Cited by 3,052
The Prognostic Value of C-Reactive Protein and Serum Amyloid A Protein in Severe Unstable Angina
Liuzzo, G., Biasucci, L. M., Gallimore, J. R., Grillo, R. L., Rebuzzi, A. G., Pepys, M. B., & Maseri, A. (1994) · New England Journal of Medicine · doi:10.1056/nejm199408183310701 · Cited by 2,357
Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses
Danesh, J. (2000) · BMJ · doi:10.1136/bmj.321.7255.199 · Cited by 1,692
Production of C-reactive protein and risk of coronary events in stable and unstable angina
Haverkate, E., Thompson, S. G., Pyke, S. D., Gallimore, J. R., & Group, M. B. P. (1997) · The Lancet · doi:10.1016/s0140-6736(96)07591-5 · Cited by 1,500
Diabetes and cardiovascular disease
Howard, B. V., & Magee, M. F. (2000) · Current Atherosclerosis Reports · doi:10.1007/s11883-000-0046-8 · Cited by 1,381
Pickup, J. C., Mattock, M. B., Chusney, G. D., & Burt, D. (1997) · Diabetologia · doi:10.1007/s001250050822 · Cited by 1,242
Research works printed but not linked: 2
- Davidson MH. Management of dyslipidemia by the patient profiles. In: The mobile lipid clinic. A companion handbook. Philedelphia: Lippincott Williams and Wilkins. 2002, 182–4.
- Tracy RP. Inflammation, the metabolicsyndrome and cardiovascular risk. Int J Clin Pract Suppl 2003,134: 10–7.
Cited by
Bahceci, M., Gokalp, D., Bahceci, S., Tuzcu, A., Atmaca, S., & Arikan, S. (2007) · Journal of Endocrinological Investigation · doi:10.1007/bf03347427 · Cited by 260
Self-citationA systematic review of anti-obesity medicinal plants - an update
Hasani-Ranjbar, S., Jouyandeh, Z., & Abdollahi, M. (2013) · Journal of Diabetes & Metabolic Disorders · doi:10.1186/2251-6581-12-28 · Cited by 224
High-Sensitivity C-Reactive Protein as Cardiovascular Risk Marker in Patients with Diabetes Mellitus
Pfützner, A., & Forst, T. (2006) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2006.8.28 · Cited by 217
Kressel, G., Trunz, B., Bub, A., Hülsmann, O., Wolters, M., Lichtinghagen, R., Stichtenoth, D. O., & Hahn, A. (2008) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2008.04.012 · Cited by 113
Mosenzon, O., Capehorn, M. S., De Remigis, A., Rasmussen, S., Weimers, P., & Rosenstock, J. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01585-7 · Cited by 91
“High-sensitivity C-reactive protein (hsCRP) is a sensitive biomarker of systemic inflammation reported to be elevated in patients with type 2 diabetes with other underlying comorbidities [3, 4].”
BackgroundAnti-inflammatory properties of antidiabetic drugs: a “promised land” in the COVID-19 era?
Katsiki, N., & Ferrannini, E. (2020) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2020.107723 · Cited by 91
Do we need to consider inflammatory markers when we treat atherosclerotic disease?
Athyros, V. G., Kakafika, A. I., Karagiannis, A. I., & Mikhailidis, D. P. (2008) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2008.02.026 · Cited by 81
Yan, Y., Li, S., Liu, Y., Bazzano, L., He, J., Mi, J., & Chen, W. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0913-2 · Cited by 82
Gohel, M. G., & Chacko, A. N. (2013) · Journal of Diabetes & Metabolic Disorders · doi:10.1186/2251-6581-12-56 · Cited by 68
“Because of a positive correlation between serum hsCRP and HbA1c, fasting insulin and HOMA-IR, inflammation, insulin resistance and hyperglycemia jointly contribute to the cardiovascular risk in type 2 DM men [22].”
Li, X., Fan, X., Ren, F., Zhang, Y., Shen, C., Ren, G., Sun, J., Zhang, N., Wang, W., Ning, G., et al. (2011) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2011.02.034 · Cited by 60
“[16] Bahceci M, Tuzcu A, Ogun C, Canoruc N, Iltimur K, Aslan C.”
BackgroundSun, J., Han, K., Xu, M., Li, L., Qian, J., Li, L., & Li, X. (2022) · Frontiers in Physiology · doi:10.3389/fphys.2022.827428 · Cited by 54
Shift Work and Metabolic Syndrome Updates: A Systematic Review
Schettini, M. A. S., Passos, R. F. D. N., & Koike, B. D. V. (2023) · Sleep Science · doi:10.1055/s-0043-1770798 · Cited by 59
Lin, S.-J., Tu, Y., Tsai, S.-C., Lai, S.-M., & Lu, H.-K. (2011) · Clinical Oral Investigations · doi:10.1007/s00784-011-0535-x · Cited by 50
“These results are contradictory to a recent randomized clinical controlled trial study of IL-6 and CRP [42] and a pilot study investigating the effect of SRP on systemic levels of CRP, fibrinogen, and white blood cell counts in subjects with and without coronary heart disease (CHD) [38].”
Ruiz, E., Gordillo‐Moscoso, A., Padilla, E., Redondo, S., Rodríguez, E., Reguillo, F., Briones, A. M., van Breemen, C., Okon, E. B., & Tejerina, T. (2006) · Diabetes · doi:10.2337/db05-0949 · Cited by 42
“CRP is an independent risk factor for cardiovascular diseases and has been found in increasing concentrations in diabetic patients (20).”
BackgroundHovens, M. M. C., Snoep, J. D., Groeneveld, Y., Frölich, M. A., Tamsma, J. T., & Huisman, M. V. (2007) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2007.00794.x · Cited by 35
Blaha, V., Andrýs, C., Šmahelová, A., Knížek, J., Hyšpler, R., Solichová, D., Blaha, M., & Zadák, Z. (2006) · Pharmacological Research · doi:10.1016/j.phrs.2006.08.005 · Cited by 33
Fronczyk, A., Molęda, P., Safranow, K., Piechota, W., & Majkowska, L. (2013) · Inflammation · doi:10.1007/s10753-013-9746-4 · Cited by 32
The Anti-Inflammatory Effect of Novel Antidiabetic Agents
Theofilis, P., Sagris, Μ., Oikonomou, E. K., Antonopoulos, A. S., Siasos, G., Tsioufis, K., & Tousoulis, D. (2022) · Life · doi:10.3390/life12111829 · Cited by 35
Mengozzi, A., Ciuceis, C. D., Dell’Oro, R., Georgiopoulos, G. A., Lazaridis, A. A., Nosalski, R., Pavlidis, G., Tual‐Chalot, S., Rosei, C. A., Anyfanti, P., et al. (2023) · Journal of Hypertension · doi:10.1097/hjh.0000000000003503 · Cited by 34
“In subjects with type 2 DM, a correlation was observed between high-sensitive CRP and IL-6 with HbA1c independent of the presence of coronary heart disease [172,173].”
BackgroundOxidative stress and insulin resistance in policemen working shifts
Demir, I., Toker, A., Zengin, S., Laloğlu, E., & Aksoy, H. (2015) · International Archives of Occupational and Environmental Health · doi:10.1007/s00420-015-1079-1 · Cited by 27
“It was showed that the positive correlation between serum hsCRP and HOMA-IR may contribute to the cardiovascular disease risk in patients with type 2 diabetes mellitus (Bahceci et al. 2005).”
BackgroundElgendi, S. S., Bakeet, M. Y., El-Hamed, E. A., Ibrahim, F. K., & Ahmed, R. I. (2008) · Journal of Cardiology · doi:10.1016/j.jjcc.2008.08.001 · Cited by 31
Inflammatory mediators involved in the progression of the metabolic syndrome
Ma, K., Jin, X., Liang, X., Zhao, Q. D., & Zhang, X. (2012) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2291 · Cited by 30
“[28] investigate the correlation among hae-”
Influence of the intervention of exercise on obese type II diabetes mellitus: A meta-analysis
Zou, Z., Cai, W., Cai, M., Xiao, M., & Wang, Z. (2015) · Primary care diabetes · doi:10.1016/j.pcd.2015.10.003 · Cited by 28
“003 erum hs-CRP has been demonstrated as being positively orrelated with HbA1c and HOMA-IR in T2DM men with or ithout coronary heart disease [30].”
BackgroundSinha, S., Misra, A., Rathi, M., Kumar, V., Pandey, R. M., Luthra, K., & Jagannathan, N. R. (2008) · Magnetic Resonance Imaging · doi:10.1016/j.mri.2008.06.001 · Cited by 22
“Recent evidence shows that C-reactive protein (CRP) is an inflammatory marker that predicts risk of coronary heart disease (CHD) [1].”
BackgroundHeo, J. M., Park, J. H., Kim, J. H., You, S., Kim, J. S., Ahn, C., Hong, S. J., Shin, K.-H., & Lim, D. (2012) · Journal of Cardiology · doi:10.1016/j.jjcc.2012.03.006 · Cited by 21
C-REACTIVE PROTEIN AND CARDIOVASCULAR DISEASE IN PEOPLE WITH DIABETES
Xu, Y., & Whitmer, K. R. (2006) · AJN American Journal of Nursing · doi:10.1097/00000446-200608000-00027 · Cited by 21
Wang, Y.-S., Ye, J., Yang, X. M., Zhang, G., Cao, Y., Zhang, R., Dai, W., & Zhang, Q. (2018) · Archives of Medical Science · doi:10.5114/aoms.2018.79565 · Cited by 14
Golan, R., Tirosh, A., Schwarzfuchs, D., Harman‐Boehm, I., Thiery, J., Fiedler, M., Blüher, M., Stümvoll, M., & Shai, I. (2011) · Nutrition · doi:10.1016/j.nut.2011.04.001 · Cited by 15
Wang, Y., Zhou, C., Yu, T., & Zhao, F. (2021) · Journal of Healthcare Engineering · doi:10.1155/2021/8476592 · Cited by 12
An Overview of Inflammatory Markers in Type 2 Diabetes from the Perspective of the Clinical Chemist
Kimberly, M. M., Cooper, G. R., & Myers, G. L. (2006) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2006.8.37 · Cited by 12
Deepika, G., Veeraiah, N., Naveed, S., & Ramana, M. (2016) · International Journal of Research in Medical Sciences · doi:10.18203/2320-6012.ijrms20160791 · Cited by 9
Insulin Resistance and Metabolic Syndrome
Li, W., & Price, R. A. (2007) · WORLD SCIENTIFIC eBooks · doi:10.1142/9789812790811_0031 · Cited by 8
Kumpatla, S., Kirubakaran, K., Sathyamurthy, I., Muthukumaran, P., Krishnan, J., Narayanamoorthy, S. K., & Viswanathan, V. (2014) · PubMed Central · Cited by 5
Tang, X., Yuan, D., Zhu, P., Xu, N., Yao, Y., Wang, P., Chen, Y., Gao, L., Song, L., Yang, Y., et al. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e23900 · Cited by 5
“Previous studies have demonstrated a relationship between elevated levels of HbA1c and an increase in inflammatory markers, such as hs-CRP [31 – 35].”
BackgroundAhmed, H. H., Shousha, W. G., El‐mezayen, H. A., Emara, I. A., & hassan, M. E. (2017) · Asian Journal of Pharmaceutical and Clinical Research · doi:10.22159/ajpcr.2017.v10i9.19524 · Cited by 5
“[91] found that hs-CRP levels are increased in patients with CHD, whether they are diabetic or non-diabetic than in controls, and the levels of hs-CRP in diabetic patient with CHD are also higher than patients with CHD only.”
BackgroundAziz, D., Mohammad, I. K., & Afraa, Z. (2023) · Research Journal of Pharmacy and Technology · doi:10.52711/0974-360x.2023.00036 · Cited by 6
Is it a supplementary benefit to use anti-inflammatory agents in the treatment of type 2 diabetes?
Patrice, N. K., Martial, D. J., & Bruno, T. P. (2017) · BMC Research Notes · doi:10.1186/s13104-017-2785-4 · Cited by 3
“also found this positive correlation, and just as us they didn’t find a correlation between hs-CRP, arterial pressure, age and body mass index [29, 30].”
Bandyopadhyay, R., Paul, R., Basu, A. K., Chakraborty, P., & Mitra, S. (2013) · Cited by 8
STUDY OF SERUM ADIPONECTIN AND HIGH SENSITIVITY C-REACTIVE PROTEIN IN DIABETIC PATIENTS
Shreshtha, S., Sharma, P., Kumar, P., Sharma, R., Gupta, S., & Mahapatra, T. (2018) · Asian Journal of Pharmaceutical and Clinical Research · doi:10.22159/ajpcr.2018.v11i7.24252 · Cited by 2
“In a follow-up study conducted by Bahceci et al. [21], escalation of CRP indicated the increased the risk of a CAD.”
ResultGoldberg, R. B. (2006) · Fundamental and clinical cardiology · doi:10.3109/9781420019667.006 · Cited by 2
Alduraywish, A. A. (2017) · Journal of Endocrinology and Metabolism · doi:10.14740/jem405w · Cited by 2
Duran, R., Marakoğlu, K., Vatansev, H., Kızmaz, M., Saraçlıgil, B., Aybatti, E., Demirci, V., & Kebapçılar, L. (2023) · Acta Endocrinologica (Bucharest) · doi:10.4183/aeb.2023.169 · Cited by 1
Eizadi, M., Zarifyan, A., Shahram, S., Khorshidi, D., & (msc, D. H. (2012) · DOAJ (DOAJ: Directory of Open Access Journals) · Cited by 1
Akbani, A. A. R., Kuthe, S. S., & Humaney, N. (2025) · International Journal of Diabetes in Developing Countries · doi:10.1007/s13410-025-01477-y · Cited by 1
“Additionally, the study noted a significant positive correlation between hs-CRP and HbA1c, FBS, and PPBS, which are the gold standards for glycemic control in T2DM patients [15].”
Kiribayashi, M., & Echizen, H. (2012) · Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences) · doi:10.5649/jjphcs.38.479
Inflammatory Mediators and C-Reactive Protein
Farmer, J. A. (2006) · Fundamental and clinical cardiology · doi:10.3109/9781420019667.012
Shukla, R. K., Chaudhary, R., Pal, A. K., & Khan, F. F. (2020) · Scholars International Journal of Biochemistry · doi:10.36348/sijb.2020.v03i01.001
Kailday, S. S., & Mahey, A. (2021) · International Journal of Advanced Research in Medicine · doi:10.22271/27069567.2021.v3.i2g.284
“CRP has a long half-life, affordability of estimation, and stability of its levels with no circadian variation, and therefore is one of the best markers of vascular inflammation ([5]).”
BackgroundHigh Sensitive C Reactive Protein (hsCRP) and Alkaline Phosphatase (ALP) in Type 2 Diabetes Patients
Martuza, N., Haque, R., Afrin, S., Morshed, A. J. M. T., Shahnaj, A., Hossain, M. T., & Zaman, M. S. (2022) · Scholars International Journal of Biochemistry · doi:10.36348/sijb.2022.v05i01.004 · Cited by 1
Dhone, P. G., Rajkumari, R., Vikas, G., & Mubeen, M. F. (2022) · International Journal of Health Sciences · doi:10.53730/ijhs.v6ns3.8844
Mosenzon, O., Capehorn, M. S., Remigis, A. D., Rasmussen, S., Weimers, P., & Rosenstock, J. (2022) · Figshare · doi:10.6084/m9.figshare.20882123
Sasanfar, B., Salehi‐Abargouei, A., Parastouei, K., Darabi, Z., Sadeghi-Nodoushan, F., Sarebanhassanabadi, M., Seyedhosseini, S. M., Hosseini, S. S., & Rostami, H. (2026) · BMC Cardiovascular Disorders · doi:10.1186/s12872-026-05749-1
Kugathasan, L., Davies, M. J., Girard, M., Moedt, E., Muskiet, M. H. A., & Cherney, D. Z. I. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71039
Metadata
- Authors
- Bahceci, M., Tuzcu, A., Ogun, C., Canoruc, N., Iltimur, K., & Aslan, C.
- Affiliations
- Dicle University (TR)
- Venue
- Journal of Endocrinological Investigation
- Published
- 2005-04
- Volume
- 28
- Issue
- 4
- Pages
- 145-150
- ISSN
- 0391-4097 (ISSN-L)
- 1720-8386
- OpenAlex
- W2062350239
- Cited by
- 53
- References
- 34
- Citations by year
- 2026: 2 · 2025: 1 · 2023: 5 · 2022: 6 · 2021: 2 · 2020: 2 · 2019: 1 · 2018: 2 · 2017: 3 · 2016: 1 · 2015: 2 · 2014: 1 · 2013: 4 · 2012: 4
- FWCI
- 3.36
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Journal of Endocrinological Investigation (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Keywords
- C-reactive protein, high-sensitivity CRP, type 2 diabetes, coronary artery disease, insulin resistance, HbA1c, fasting insulin, HOMA-IR, inflammation, hyperglycemia, cardiovascular risk, men, lipid profile, triglycerides, HDL cholesterol, LDL cholesterol, VLDL cholesterol
- MeSH terms
- Adult, Blood Glucose, C-Reactive Protein, Coronary Disease, Diabetes Mellitus, Type 2, Fasting, Glycated Hemoglobin, Homeostasis, Humans, Insulin, Insulin Resistance, Cholesterol, HDL, Male, Middle Aged, Osmolar Concentration, Case-Control Studies
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.